Q2 FY27: Revenue up 55% YoY to Rs 585M, PAT at Rs 40.5M
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 6.7 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NURECA reported Q2 FY26-27 standalone revenue of Rs 585.99M (vs Rs 378.41M) and PAT of Rs 36.22M (vs Rs 31.40M). Consolidated revenue was Rs 585.26M (vs Rs 377.40M) and PAT Rs 40.51M. H1 consolidated revenue grew about 37.5% to Rs 988.69M and PAT jumped roughly 60% to Rs 71.18M. Auditor Singhi and Co issued an unqualified limited review. However, H1 operating cash flow turned negative at minus Rs 125.38M against positive Rs 44.46M last year, driven by higher inventory and trade receivables.
Strong revenue and profit growth is positive, but negative operating cash flow from rising inventory and receivables is a watch point.